Vistin Pharma ASA: First quarter 2024 financial results
Oslo, Norway, 24th of April 2024
Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2024.
Revenue in the first quarter ended at MNOK 104 compared to MNOK 101 in Q1 2023. Sales volume in the quarter was up by 11% compared to Q1 2023.
First quarter EBITDA ended at MNOK 20 compared to MNOK 14 in Q1 2023, representing a 45% increase. EBITDA positively affected by increased sales volume and product mix, partly offset by a one-time inventory adjustment of MNOK 7.
The net profit ended at MNOK 7.7 for the first quarter of 2024. Net profit negatively affected with approx. MNOK 3 in the quarter by fair value of future FX cash flow hedging contracts (unrealized gain - no cash effect in quarter).
Unplanned “wear and tear” maintenance/repair on Line 2 resulted in lower than planned production and sales volume in the first quarter. After the repair, line 2 has been producing according to plan from fiscal week 14.
The first quarter conference call, which will be held today 24th of April at 8.30am (CET), will be available via webcast and audio through the following access points:
Webcast:
https://edge.media-server.com/mmc/p/79s7jnyd
Telephone conference (online registration):
https://register.vevent.com/register/BI321b77b12df846a1884e7ce3a77e0b1a
The conference call will be held in English.
Please find the Q1 report and presentation enclosed. The report will also be made available on www.vistin.com.
*****
For further information, please contact:
Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia6.5.2024 11:00:00 CEST | Press release
Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed early signs of potential efficacy.1 DMI is a common, irreversible complication of diabetic retinopathy (DR) that may lead to blindness.12,3,4 It can develop when the light sensitive tissues of the central retina do not receive adequate blood supply over a longer time. There are currently no approved treatments for DMI. The current standard of care for advanced DR includes intravitreal anti-VEGF treatment or invasive laser treatment. However, some patients’ conditions progress despite this treatment.5 BI 764524 uses a novel mode of action by inhibiting the Sema3A pathway to re-vascularize ischemic areas and potentia
Orion Corporation: Managers’ transactions – Eija Ronkainen6.5.2024 11:00:00 CEST | Press release
ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST Orion Corporation: Managers’ transactions – Eija Ronkainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Eija Ronkainen Position: Member of the Board/Deputy member Issuer: Orion Oyj LEI: 74370029VAHCXDR7B745 Notification type: INITIAL NOTIFICATION Reference number: 61636/4/4 ____________________________________________ Transaction date: 2024-05-03 Outside a trading venue Instrument type: SHARE ISIN: FI0009014377 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details (1): Volume: 556 Unit price: 0 EUR Aggregated transactions (1): Volume: 556 Volume weighted average price: 0 EUR Ori
Orion Corporation: Managers’ transactions – Henrik Stenqvist6.5.2024 11:00:00 CEST | Press release
ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST Orion Corporation: Managers’ transactions – Henrik Stenqvist Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Henrik Stenqvist Position: Member of the Board/Deputy member Issuer: Orion Oyj LEI: 74370029VAHCXDR7B745 Notification type: INITIAL NOTIFICATION Reference number: 61645/4/4 ____________________________________________ Transaction date: 2024-05-03 Outside a trading venue Instrument type: SHARE ISIN: FI0009014377 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details (1): Volume: 556 Unit price: 0 EUR Aggregated transactions (1): Volume: 556 Volume weighted average price: 0 EUR
Orion Corporation: Managers’ transactions – Maziar Mike Doustdar6.5.2024 11:00:00 CEST | Press release
ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST Orion Corporation: Managers’ transactions – Maziar Mike Doustdar Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Maziar Doustdar Position: Member of the Board/Deputy member Issuer: Orion Oyj LEI: 74370029VAHCXDR7B745 Notification type: INITIAL NOTIFICATION Reference number: 61578/4/4 ____________________________________________ Transaction date: 2024-05-03 Outside a trading venue Instrument type: SHARE ISIN: FI0009014377 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details (1): Volume: 556 Unit price: 0 EUR Aggregated transactions (1): Volume: 556 Volume weighted average price: 0
Orion Corporation: Managers’ transactions – Veli-Matti Mattila6.5.2024 11:00:00 CEST | Press release
ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST Orion Corporation: Managers’ transactions – Veli-Matti Mattila Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Veli-Matti Mattila Position: Member of the Board/Deputy member Issuer: Orion Oyj LEI: 74370029VAHCXDR7B745 Notification type: INITIAL NOTIFICATION Reference number: 61609/5/4 ____________________________________________ Transaction date: 2024-05-03 Outside a trading venue Instrument type: SHARE ISIN: FI0009014377 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details (1): Volume: 1112 Unit price: 0 EUR Aggregated transactions (1): Volume: 1112 Volume weighted average price: